PT2942082T - Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento - Google Patents

Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Info

Publication number
PT2942082T
PT2942082T PT15165962T PT15165962T PT2942082T PT 2942082 T PT2942082 T PT 2942082T PT 15165962 T PT15165962 T PT 15165962T PT 15165962 T PT15165962 T PT 15165962T PT 2942082 T PT2942082 T PT 2942082T
Authority
PT
Portugal
Prior art keywords
treatment
movement disorders
receptor antogonists
antogonists
receptor
Prior art date
Application number
PT15165962T
Other languages
English (en)
Inventor
Kase Hiroshi
Karasawa Akira
Mori Akihisa
Waki Yutaka
Ohsawa Yutaka
Kuwana Yoshihisa
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2942082(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of PT2942082T publication Critical patent/PT2942082T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT15165962T 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento PT2942082T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35241302P 2002-01-28 2002-01-28

Publications (1)

Publication Number Publication Date
PT2942082T true PT2942082T (pt) 2019-06-06

Family

ID=27663091

Family Applications (2)

Application Number Title Priority Date Filing Date
PT10179406T PT2260850T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
PT15165962T PT2942082T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT10179406T PT2260850T (pt) 2002-01-28 2003-01-28 Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento

Country Status (16)

Country Link
US (7) US20040198753A1 (pt)
EP (4) EP2044940A3 (pt)
JP (3) JP4376630B2 (pt)
KR (5) KR101166000B1 (pt)
CN (3) CN101543497A (pt)
AU (2) AU2003207734C1 (pt)
BR (1) BR0306919A (pt)
CA (2) CA2473864C (pt)
CO (1) CO5601022A2 (pt)
EA (1) EA200400982A1 (pt)
ES (2) ES2716404T3 (pt)
HU (2) HUE043353T2 (pt)
MX (1) MXPA04007299A (pt)
PT (2) PT2260850T (pt)
TR (1) TR201903603T4 (pt)
WO (1) WO2003063876A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CN101543497A (zh) * 2002-01-28 2009-09-30 协和发酵工业株式会社 治疗运动疾病患者的方法
WO2004019949A1 (en) 2002-08-30 2004-03-11 Kyowa Hakko Kogyo Co. Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
JP2006514697A (ja) * 2002-12-19 2006-05-11 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニストの使用
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006058781A2 (en) * 2004-12-03 2006-06-08 Proteosys Ag Finasteride, dutasteride and related compounds for preventing/treating neurologically-associated disorders
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
EP1902716A4 (en) * 2005-06-07 2009-05-13 Kyowa Hakko Kirin Co Ltd PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR MOTOR TROUBLESHOOTING
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US8802002B2 (en) 2006-12-28 2014-08-12 3M Innovative Properties Company Dimensionally stable bonded nonwoven fibrous webs
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
US20090118376A1 (en) * 2007-11-02 2009-05-07 Ru-Band Lu Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia
US9826921B2 (en) * 2008-06-12 2017-11-28 Global Kinetics Corporation Limited Detection of hypokinetic and hyperkinetic states
US20120053182A1 (en) * 2009-01-20 2012-03-01 Schering Corporation Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
EP2626456B1 (en) * 2010-10-05 2018-03-21 JNC Corporation Multilayered non-woven fabric and product thereof
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
HK1201741A1 (en) * 2012-06-05 2015-09-11 International Stem Cell Corporation Method of prevention of neurological diseases
US9012640B2 (en) * 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
AU2014223313B2 (en) 2013-03-01 2018-07-19 Global Kinetics Pty Ltd System and method for assessing impulse control disorder
US10040817B2 (en) 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
JP6381883B2 (ja) * 2013-10-04 2018-08-29 国立大学法人千葉大学 不随意運動の予防及び／又は治療組成物
WO2015131244A1 (en) 2014-03-03 2015-09-11 Global Kinetics Corporation Pty Ltd Method and system for assessing motion symptoms
WO2016148260A1 (ja) * 2015-03-17 2016-09-22 協和発酵キリン株式会社 医薬組成物
WO2016204939A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
US10973815B2 (en) 2016-03-31 2021-04-13 Versi Group, Llc Delta opioid agonist mu opioid antagonist compositions and methods for treating Parkinsons disease
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
JPWO2020189781A1 (ja) 2019-03-21 2021-06-03 協和キリン株式会社 パーキンソン病治療剤
EP3714888A1 (en) * 2019-03-25 2020-09-30 Assistance Publique - Hôpitaux De Paris Compounds for use in the treatment of adcy5-related dyskinesia
US10758535B1 (en) * 2019-04-26 2020-09-01 Sumitomo Dainippon Pharma Co., Ltd. Therapeutic drug for dyskinesia
JP7382737B2 (ja) * 2019-05-13 2023-11-17 東和薬品株式会社 イストラデフィリン製剤
JP7801234B2 (ja) 2020-03-10 2026-01-16 マーベル・バイオテクノロジー 障害を処置するためのプリン化合物
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator
TW202345782A (zh) 2022-04-27 2023-12-01 日商衛材R&D企管股份有限公司 帕金森氏症治療用醫藥組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69130869T2 (de) 1990-10-18 1999-06-10 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Xanthinderivate
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
PT628311E (pt) 1992-07-08 2002-09-30 Kyowa Hakko Kogyo Kk Derivado de xantina com actividade antidepressiva
EP0666079B1 (en) 1993-07-27 2001-11-07 Kyowa Hakko Kogyo Co., Ltd. Remedy for parkinson's disease
CA2161011A1 (en) 1994-02-23 1995-08-31 Fumio Suzuki Xanthine derivatives
JP4195729B2 (ja) 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
EP0975345A1 (en) * 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
WO1999043678A1 (en) 1998-02-24 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for parkinson's disease
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
IL142128A0 (en) 1998-09-22 2002-03-10 Kyowa Hakko Kogyo Kk [1,2,4] triazolo [1,5-c] pyrimidine derivatives
WO2000069464A1 (en) 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Novel use
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
FR2796759B1 (fr) 1999-07-23 2001-11-02 Gemplus Card Int Minicarte a circuit integre et procede pour son obtention
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
AUPQ441499A0 (en) 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
JP4064671B2 (ja) 2000-02-25 2008-03-19 エフ．ホフマン−ラ ロシュ アーゲー アデノシン受容体モジュレーター
KR20070058022A (ko) 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
SI1283839T1 (pt) 2000-05-26 2005-08-31 Schering Corp
AU8181701A (en) 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
JP4251868B2 (ja) 2000-08-11 2009-04-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 ２−アミノピリジン化合物および医薬用途
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
MXPA03009185A (es) * 2001-04-09 2004-02-17 Neurosearch As Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
CN101543497A (zh) * 2002-01-28 2009-09-30 协和发酵工业株式会社 治疗运动疾病患者的方法
WO2004019949A1 (en) * 2002-08-30 2004-03-11 Kyowa Hakko Kogyo Co. Ltd. Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
ATE481101T1 (de) * 2003-06-10 2010-10-15 Kyowa Hakko Kirin Co Ltd Verfahren zur behandlung von angstzuständen
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US9238003B2 (en) * 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules

Also Published As

Publication number Publication date
TR201903603T4 (tr) 2019-04-22
CN101822676A (zh) 2010-09-08
EP2260850A2 (en) 2010-12-15
AU2008200611A1 (en) 2008-03-06
CO5601022A2 (es) 2006-01-31
KR101166000B1 (ko) 2012-07-16
US20060178379A1 (en) 2006-08-10
KR20040077763A (ko) 2004-09-06
JP5171556B2 (ja) 2013-03-27
AU2008200611B2 (en) 2011-12-15
US20170196872A1 (en) 2017-07-13
PT2260850T (pt) 2018-10-24
KR20110010829A (ko) 2011-02-07
EA200400982A1 (ru) 2004-12-30
CN1646132A (zh) 2005-07-27
JP2005523898A (ja) 2005-08-11
WO2003063876A2 (en) 2003-08-07
ES2686123T3 (es) 2018-10-16
EP2044940A2 (en) 2009-04-08
JP2009067807A (ja) 2009-04-02
CA2473864A1 (en) 2003-08-07
JP5612016B2 (ja) 2014-10-22
US20140249166A1 (en) 2014-09-04
US7727994B2 (en) 2010-06-01
US20060148827A1 (en) 2006-07-06
CA2813048A1 (en) 2003-08-07
KR20120103740A (ko) 2012-09-19
EP1469855A2 (en) 2004-10-27
BR0306919A (pt) 2004-11-09
CN101543497A (zh) 2009-09-30
WO2003063876A3 (en) 2003-11-27
KR20150080013A (ko) 2015-07-08
MXPA04007299A (es) 2004-10-29
EP2044940A3 (en) 2010-11-10
HUE043353T2 (hu) 2019-08-28
HUE039348T2 (hu) 2018-12-28
ES2716404T3 (es) 2019-06-12
JP4376630B2 (ja) 2009-12-02
EP2260850B1 (en) 2018-07-04
US7727993B2 (en) 2010-06-01
AU2003207734B2 (en) 2008-02-21
KR101098209B1 (ko) 2011-12-23
US20040198753A1 (en) 2004-10-07
US20180221377A1 (en) 2018-08-09
EP2942082B1 (en) 2019-03-06
KR20100056569A (ko) 2010-05-27
AU2003207734C1 (en) 2009-10-08
JP2012140461A (ja) 2012-07-26
EP2942082A3 (en) 2016-01-27
EP2942082A2 (en) 2015-11-11
CA2473864C (en) 2013-06-11
EP2260850A3 (en) 2013-11-13
US20120122897A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
PT2942082T (pt) Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
AU2003286567A8 (en) Methods for the treatment of skin disorders
HUS2200036I1 (hu) Dihidroimidazolonok alkalmazása kutyák kezelésére
AU2003285091A8 (en) Interferon antagonists useful for the treatment of interferon related diseases
AU2003226927A8 (en) Novel carboxamide compounds for use in mch receptor related disorders
AU2003228819A8 (en) Combinations for the treatment of inflammatory skin disorders
IL165394A0 (en) Use of thio-oxindole derivatives in treatment of skin disorders
IL172564A0 (en) N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF THE 5HT2c RECEPTOR ASSOCIATED DISEASES
IL164697A0 (en) N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
PL369822A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
ZA200802552B (en) Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
ZA200505989B (en) Use the steroids to treat ocular disorders
EP1613318A4 (en) COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES
ZA200803236B (en) Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders
IL178427A0 (en) 1,2-diarylimidazole-4-carboxamide compounds, processes for their preparation and use thereof in the treatment of obesity, psychiatric and neurological disorders
GB0219660D0 (en) Therapeutic use
ZA200405853B (en) Use of adapalene for the treatment of dermatological disorders
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
AU2003297912A8 (en) Methods for screening compounds for use in the treatment of disease
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
AU2003299468A8 (en) Dc-sign isoforms, related compositions and methods for their use in disease therapy
PL374077A1 (en) Use of 5-ht2 receptor antagonists for the treatment of sleep disorders
AU2003248679A8 (en) Treating disease using radium-225
GB0213575D0 (en) Treatment for movement disorders